Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price
€340.8 0%
to add to portfolio
AI Score
-
Alternative
8 -
Fundamental
8 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Vertex Pharmaceuticals Incorporated, AI stock picks, stock alerts and much more.
VX1.DE AI Stock Analysis
AI stock analysis for VX1.DE is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Vertex Pharmaceuticals Incorporated (VX1.DE) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Vertex Pharmaceuticals Incorporated (VX1.DE) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Vertex Pharmaceuticals Incorporated (VX1.DE), currently trading at €340.8, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About VX1.DE
-
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
-
Symbol
VX1.DE
-
Market
XETRA
-
Industry
Biotechnology
-
Market Cap
87.4B
Similar Stocks
 |
CureVac 5CV.F |
€4.64 1% |
5 |
 |
BioNTech SE 22UA.F |
€95.8 0.2% |
5 |
 |
Novavax NVV1.F |
€6.74 1.8% |
3 |
 |
Heidelberg Pharma AG HPHA.DE |
€4.38 1.4% |
7 |
 |
Formycon AG FYB.DE |
€24.5 1.5% |
6 |
News
VX1.DE Alternative Data
Web Traffic
Vertex Pharmaceuticals Incorporated receives an estimated 317601 monthly visitors to vrtx.com.
-
Web Traffic
317601
-
Change from Previous Month
14.1%
-
3 Month Change
16%
-
YoY Change
16%
Twitter Followers
Vertex Pharmaceuticals Incorporated has 70,835 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.1% over the last month.
-
Twitter Followers
70835
-
Daily Change
0%
-
1 Month Change
0.1%
-
3 Month Change
0.2%
-
YoY Change
0.2%
Facebook Engagement
Vertex Pharmaceuticals Incorporated has engaged 2,552 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
2552
-
Daily Change
29.6%
-
1 Month Change
36.2%
-
3 Month Change
20.8%
-
YoY Change
20.8%
Instagram Followers
Vertex Pharmaceuticals Incorporated has 12,820 Instagram Followers on its main Instagram account, up by 0.8% over the last month.
-
Instagram Followers
12820
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
9%
Youtube Subscribers
Vertex Pharmaceuticals Incorporated has 2,920 subscribers on its main Youtube channel, up by 3.9% over the last month.
-
Youtube Subscribers
2920
-
Daily Change
0%
-
1 Month Change
3.9%
-
3 Month Change
10.2%
-
YoY Change
10.2%
Job Postings
Vertex Pharmaceuticals Incorporated has an estimated 152 open job postings, which is down -11.1% over the last month.
-
Job Postings
152
-
Daily Change
0%
-
1 Month Change
11.1%
-
3 Month Change
26.9%
-
YoY Change
26.9%
Reddit Mentions
Vertex Pharmaceuticals Incorporated has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
490,130 are following Vertex Pharmaceuticals Incorporated on LinkedIn, up by 2.7% over the last month.
-
LinkedIn Followers
490130
-
Daily Change
2.7%
-
1 Month Change
2.7%
-
3 Month Change
8.1%
-
YoY Change
8.1%
LinkedIn Employees
According to LinkedIn, Vertex Pharmaceuticals Incorporated has 6,037 employees, up by 0.4% over the last month.
-
LinkedIn Employees
6037
-
Daily Change
0.4%
-
1 Month Change
0.4%
-
3 Month Change
2.8%
-
YoY Change
2.8%
Business Outlook
According to employee reviews, the business outlook among employees at Vertex Pharmaceuticals Incorporated is 88 out of 100 (very bullish).
-
Business Outlook
88
-
Change from Previous Month
1.1%
-
3 Month Change
1.1%
-
YoY Change
1.1%
News Mentions
Vertex Pharmaceuticals Incorporated was mentioned 2 times in the news yesterday.
-
News Mentions
2
-
Daily Change
50%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
VX1.DE Financials
VX1.DE Key Metrics
-
Total Revenue
$2.8B
-
Net Income
$646.3M
-
Earnings per Share
$2.52
-
Free cash flow
$778.2M
-
EBITDA
$781.8M
-
EBITDA Ratio
0.282218
-
Total Assets
$22.9B
VX1.DE 2-year Revenue & Income
VX1.DE 2-year Free Cash Flow
VX1.DE Technicals
VX1.DE SMA
VX1.DE RSI
FAQ
What's the current price of Vertex Pharmaceuticals Incorporated (VX1.DE) Stock?
The price of an Vertex Pharmaceuticals Incorporated (VX1.DE) share is €340.8.
What's the market cap of Vertex Pharmaceuticals Incorporated?
The current market cap of Vertex Pharmaceuticals Incorporated is 87.4B.
Should I buy or sell VX1.DE?
Multiple alternative data signals suggest that Vertex Pharmaceuticals Incorporated stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Vertex Pharmaceuticals Incorporated a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Vertex Pharmaceuticals Incorporated stock. The bullish indicators suggest that Vertex Pharmaceuticals Incorporated's growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Vertex Pharmaceuticals Incorporated (VX1.DE) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Vertex Pharmaceuticals Incorporated stock, given the bullish outlook.
What are some stocks similar to Vertex Pharmaceuticals Incorporated (VX1.DE) that investors often compare it to?
Vertex Pharmaceuticals Incorporated (VX1.DE) is often compared to similar stocks such as CureVac, BioNTech SE, Novavax, Heidelberg Pharma AG and Formycon AG.
What is the forecast for Vertex Pharmaceuticals Incorporated's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Vertex Pharmaceuticals Incorporated's stock price to be around €373.2 in 2026. Starting from the current price of €340.8, this represents a 9.5% change in price, indicating a bullish outlook for the stock.
How to buy Vertex Pharmaceuticals Incorporated (VX1.DE) Stock?
Vertex Pharmaceuticals Incorporated stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Vertex Pharmaceuticals Incorporated shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.